Cellectar Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Cellectar Biosciences, Inc. (CLRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $113.91 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-03-04
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-03-31 was $14.16, a 482.72% increase year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2022-03-31 was $2.43, a 58.39% decline year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2021-03-31 was $5.84.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2016-03-31 was $122.06, a 794.21% increase year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2025 was $113.91, a 2.90% increase from fiscal 2024.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $110.70, a 894.61% increase from fiscal 2023.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $11.13, a 44.13% decline from fiscal 2022.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $19.92, a 43.31% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $113.91 10-K · filed 2026-03-04 | ||||
| 2024-12-31 | $110.70 10-K · filed 2026-03-04 | $3.69 10-K · filed 2025-03-13 | |||
| 2023-12-31 | $11.13 10-K · filed 2025-03-13 | ||||
| 2023-03-31 | $14.16 10-Q · filed 2023-05-04 | ||||
| 2022-12-31 | $19.92 10-K/A · filed 2024-10-29 | ||||
| 2022-09-30 | $20.41 10-Q · filed 2022-11-03 | ||||
| 2022-06-30 | $20.70 10-Q · filed 2022-08-05 | ||||
| 2022-03-31 | $2.43 10-Q · filed 2023-05-04 | ||||
| 2021-12-31 | $13.90 10-K · filed 2023-03-09 | $1.39 10-K · filed 2022-03-21 | |||
| 2021-09-30 | $42.40 10-Q · filed 2022-11-03 | ||||
| 2021-06-30 | $42.40 10-Q · filed 2022-08-05 | ||||
| 2021-03-31 | $5.84 10-Q · filed 2022-05-10 | ||||
| 2020-12-31 | $6.62 10-K · filed 2022-03-21 | ||||
| 2019-12-31 | $10.62 10-K · filed 2021-03-02 | ||||
| 2018-12-31 | $42.42 10-K · filed 2020-03-09 | ||||
| 2017-12-31 | $77.40 10-K · filed 2019-02-26 | $7.74 10-K · filed 2018-03-21 | |||
| 2016-12-31 | $20.03 10-K · filed 2018-03-21 | ||||
| 2016-09-30 | $46.68 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $88.67 10-Q · filed 2016-08-11 | ||||
| 2016-03-31 | $122.06 10-Q · filed 2016-05-12 | ||||
| 2015-12-31 | $125.70 10-K · filed 2017-03-15 | ||||
| 2015-03-31 | $13.65 10-Q · filed 2015-05-20 | ||||
| 2014-12-31 | $145.50 10-K/A · filed 2016-10-20 | $14.55 10-K · filed 2015-03-24 | |||
| 2013-12-31 | $17.60 10-K · filed 2015-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |